Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Targeting human epidermal factor receptor 2 (HER2) therapy have shown the anti-tumor efficacy
in patients with HER2-positive gastrointestinal tumors. Pyrotinib is an irreversible
small-molecule receptor tyrosine kinase inhibitor targeting both epidermal growth factor
receptor (EGFR) and HER2. This study is designed to evaluate the efficacy and safety of
Pyrotinib in patients with HER2 positive gastrointestinal tumors.